

---

## NextCell Pharma Q2 2024/2025 - No cow on the ice

Redeye updates its view on NextCell following an uneventful Q2 2024/2025 report and the company's operational update, which offered new perspectives on recent data and subsidiary developments. While making minor revisions to our estimates, we maintain our view of the case.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**NextCell Pharma Q2 2024/2025 - No cow on the ice**